InterMune, Inc. and Roche Holdings, Inc. v. W. Scott Harkonen, M.D.

CourtCourt of Chancery of Delaware
DecidedMay 10, 2023
Docket2021-0694-NAC
StatusPublished

This text of InterMune, Inc. and Roche Holdings, Inc. v. W. Scott Harkonen, M.D. (InterMune, Inc. and Roche Holdings, Inc. v. W. Scott Harkonen, M.D.) is published on Counsel Stack Legal Research, covering Court of Chancery of Delaware primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
InterMune, Inc. and Roche Holdings, Inc. v. W. Scott Harkonen, M.D., (Del. Ct. App. 2023).

Opinion

IN THE COURT OF CHANCERY OF THE STATE OF DELAWARE

INTERMUNE, INC., and ROCHE ) HOLDINGS, INC., ) ) Plaintiffs, ) ) v. ) C.A. No. 2021-0694-NAC ) W. SCOTT HARKONEN, M.D., ) ) Defendant. )

MEMORANDUM OPINION

Date Submitted: April 3, 2023 Date Decided: May 10, 2023

Karen A. Jacobs, Megan W. Cascio, Courtney Kurz, MORRIS, NICHOLS, ARSHT & TUNNELL LLP, Wilmington, Delaware; Laurie Carr Mims, Benjamin D. Rothstein, Candice Mai Khanh Nguyen, Melissa Cornell, Catherine C. Porto, KEKER, VAN NEST & PETERS LLP, San Francisco, California; Counsel for Plaintiffs InterMune, Inc., and Roche Holdings, Inc.

Michael A. Weidinger, Megan Ix Brison, PINCKNEY, WEIDINGER, URBAN & JOYCE LLC, Wilmington, Delaware; Elizabeth Sandza, Richard W. Sandza, SANDZA LAW, PLLC, Washington, District of Columbia; Counsel for Defendant W. Scott Harkonen, M.D.

COOK, V.C. Defendant Dr. W. Scott Harkonen is the founder and former CEO of

InterMune, Inc. (the “Company”). In 2009, Harkonen was convicted of wire fraud.

A federal jury found beyond a reasonable doubt that Harkonen acted with an intent

to defraud when he directed the Company to issue a false and misleading press

release about the results of one of the Company’s clinical trials.

Harkonen litigated the validity of his conviction for over nine years. He

challenged the evidence of his intent after trial, on appeal, collaterally, and in the

Supreme Court of the United States. Top-tier lawyers advocated for him in every

challenge and provided constitutionally effective assistance. Every challenge failed.

Having exhausted judicial avenues for overturning his conviction, Harkonen

sought clemency from the President of the United States. In 2021, then-President

Trump pardoned Harkonen’s conviction. The pardon did not expunge Harkonen’s

conviction or declare him innocent of wire fraud. Instead, the pardon restored the

basic civil rights that any federal felony conviction removes.

The Company and its insurers advanced Harkonen’s defense costs. After

Harkonen was convicted, the insurers invoked a policy exclusion for crimes

involving intentional fraud to seek repayment from the Company of a portion of the

sums they had advanced. During arbitration, the Company argued that Harkonen’s

conduct did not fit the plain language of the exclusion. The arbitrators rejected the

Company’s argument and ordered the Company to repay the insurers. Through this action, the Company seeks a declaration that Harkonen is not

entitled to indemnification. The parties have cross moved for summary judgment

on two questions of law. The first is whether, under Section 145(c) of the Delaware

General Corporation Law, a presidential pardon renders a corporate officer

“successful on the merits or otherwise.” The second is whether a corporate officer

who has been convicted of federal wire fraud may relitigate the issue of “good faith”

under Section 145(a) when the guilty verdict necessarily determined that the officer

acted in bad faith and the officer had a full and fair opportunity to challenge the

verdict. The answer to both questions is no.

Under Section 145(c), a successful outcome in a criminal action is anything

other than a conviction. Harkonen was convicted. So he was not successful.

A presidential pardon does not erase the conviction or operate as a

determination of innocence. Harkonen’s pardon explains that.

To redefine success, Harkonen argues that the pardon restored his civil rights.

He says Section 145(c) indemnification was a “basic civil right” eliminated by his

conviction such that denying him indemnification would impermissibly punish him

for a pardoned crime. Corporate indemnification is indeed important, but it is not a

basic civil right. Basic civil rights are fundamental rights. Indemnification offered

to corporate officials under a state statute is not a right that belongs to every United

States citizen.

2 Even so, the basic civil rights maneuver stumbles over Section 145(c)’s text.

Section 145(c) indemnification is not unconditional; it depends on success. A

conviction is not success. And the pardon did not overturn Harkonen’s conviction.

So even if, somehow, corporate officer indemnification qualified as a basic civil

right restored by a federal pardon, Harkonen never lost it because he never had it.

Harkonen’s Section 145(a) arguments fare no better. The Company chose to

treat as mandatory the permissive indemnification provided under Section 145(a).

But that choice did not modify the statute. An officer is not entitled to

indemnification under Section 145(a) unless the officer acted in good faith. Bad

faith is an element of wire fraud. A jury found Harkonen guilty of wire fraud.

Multiple courts affirmed. And the pardon did not vacate any of the judgments.

Precedent explains that a conviction based on bad faith is conclusive evidence of a

failure to act in good faith. So Harkonen cannot litigate his state of mind anymore.

To undermine the preclusive effect of his conviction, Harkonen raises a

number of issues that, according to him, render his conviction infirm. He contends,

for example, that after he was convicted, the Supreme Court of the United States

validated the statistical methods he used to reach the conclusions in the press release

that were found fraudulent. But this argument—and all the others—were already

considered and rejected during Harkonen’s criminal proceedings. Were Harkonen

to reassert those arguments in federal court today, they would be procedurally barred

3 under post-conviction rules. The indemnification phase of a Section 145 proceeding

is not a means of collateral attack. The General Assembly did not enact Section 145

to give directors and officers of Delaware corporations an additional vehicle for post-

conviction review.

Harkonen alternatively invokes the judicial admissions doctrine. He insists

that because the Company told arbitrators he did not act with an intent to defraud,

the Company cannot now argue that he acted in bad faith. But the Company’s

argument was, if anything, an interpretation of its insurance contracts. The judicial

admissions doctrine does not apply to legal arguments.

Harkonen’s position also overlooks that Section 145 prohibits a Delaware

corporation from indemnifying bad faith conduct. The Company cannot “admit”

that, despite a conviction conclusively establishing that he acted in bad faith,

Harkonen is entitled to indemnification under Section 145(a).

Harkonen’s motion for summary judgment is therefore denied. The

Company’s cross motion for summary judgment is granted.

4 I. FACTUAL BACKGROUND

The material facts are undisputed or are not subject to reasonable dispute. 1

A. The Parties

The Company is a Delaware corporation that commercializes drug treatments.

Harkonen served as the Company’s CEO from 1998 until 2003. Plaintiff Roche

Holdings, Inc. acquired the Company and, through the merger agreement, agreed to

honor the Company’s indemnification obligations.2

B. The Criminal Proceedings

In 2002, the Company issued a press release. The press release announced

the results of a clinical trial that the Company conducted on one of its drug products,

“Actimmune.” According to the press release, the clinical study’s results showed

Free access — add to your briefcase to read the full text and ask questions with AI

Related

United States v. Sirang
70 F.3d 588 (Eleventh Circuit, 1995)
Ex Parte Garland
71 U.S. 333 (Supreme Court, 1867)
United States v. Klein
80 U.S. 128 (Supreme Court, 1872)
United States v. Pomponio
429 U.S. 10 (Supreme Court, 1976)
Parklane Hosiery Co. v. Shore
439 U.S. 322 (Supreme Court, 1979)
United States v. Frady
456 U.S. 152 (Supreme Court, 1982)
Kremer v. Chemical Construction Corp.
456 U.S. 461 (Supreme Court, 1982)
Anderson v. Liberty Lobby, Inc.
477 U.S. 242 (Supreme Court, 1986)
McCleskey v. Zant
499 U.S. 467 (Supreme Court, 1991)
Astoria Federal Savings & Loan Ass'n v. Solimino
501 U.S. 104 (Supreme Court, 1991)
Parke v. Raley
506 U.S. 20 (Supreme Court, 1993)
Nixon v. United States
506 U.S. 224 (Supreme Court, 1993)
Herrera v. Collins
506 U.S. 390 (Supreme Court, 1993)
Logan v. United States
552 U.S. 23 (Supreme Court, 2007)
United States v. Bowling
619 F.3d 1175 (Tenth Circuit, 2010)
United States v. Schaffer, Archibald
240 F.3d 35 (D.C. Circuit, 2001)
Matrixx Initiatives, Inc. v. Siracusano
131 S. Ct. 1309 (Supreme Court, 2011)
James Rolf Bjerkan v. United States
529 F.2d 125 (Seventh Circuit, 1975)
United States v. Wayburn D. Sanders
834 F.2d 717 (Eighth Circuit, 1987)

Cite This Page — Counsel Stack

Bluebook (online)
InterMune, Inc. and Roche Holdings, Inc. v. W. Scott Harkonen, M.D., Counsel Stack Legal Research, https://law.counselstack.com/opinion/intermune-inc-and-roche-holdings-inc-v-w-scott-harkonen-md-delch-2023.